Financial & competing interests disclosure
This publication was supported by funds provided by Grant No. 5U01AI061142-02 from the National Institutes of Health, National Institute of Allergy and Infectious Diseases. Its contents are solely the responsibility of the author and do not necessarily represent the official views of the National Institutes of Health, National Institute of Allergy and Infectious Diseases. The author performs consultancy work for Vaxine Pty Ltd, the company developing Advax and other adjuvants. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.